Merck & Company, Inc. (NYSE:MRK) Lifted to Buy at Citigroup Inc.

Merck & Company, Inc. (NYSE:MRK) was upgraded by equities research analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating in a research note issued on Wednesday, October 18th, MarketBeat Ratings reports. The firm presently has a $72.00 target price on the stock. Citigroup Inc.’s price target points to a potential upside of 16.15% from the company’s current price.

A number of other brokerages also recently issued reports on MRK. HSBC Holdings plc raised shares of Merck & from a “reduce” rating to a “hold” rating in a report on Wednesday, August 9th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Merck & from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. UBS AG raised their price objective on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, July 31st. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $74.00 price objective (up from $70.00) on shares of Merck & in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $70.67.

Merck & (MRK) opened at 61.99 on Wednesday. The company has a market capitalization of $169.07 billion, a PE ratio of 33.56 and a beta of 0.80. The stock has a 50 day moving average price of $64.48 and a 200-day moving average price of $63.70. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.93 EPS. On average, equities analysts predict that Merck & will post $3.87 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Merck & Company, Inc. (NYSE:MRK) Lifted to Buy at Citigroup Inc.” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/merck-company-inc-mrk-raised-to-buy-at-citigroup-inc.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Krilogy Financial LLC boosted its position in shares of Merck & by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock worth $201,000 after buying an additional 11 shares in the last quarter. HM Capital Management LLC boosted its position in shares of Merck & by 0.4% in the 1st quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after buying an additional 15 shares in the last quarter. Balentine LLC boosted its position in shares of Merck & by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after buying an additional 20 shares in the last quarter. RB Capital Management LLC boosted its position in shares of Merck & by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after buying an additional 23 shares in the last quarter. Finally, Baystate Wealth Management LLC boosted its position in shares of Merck & by 0.4% in the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after buying an additional 27 shares in the last quarter. Institutional investors own 72.86% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply